Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 1
1978 1
1994 2
1996 3
2000 2
2001 2
2002 4
2003 4
2004 3
2005 3
2006 4
2007 1
2008 5
2009 3
2010 3
2011 2
2012 3
2013 1
2014 1
2015 3
2016 1
2020 2
2021 7
2022 7
2023 9
2024 3
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Results by year

Filters applied: . Clear all
Page 1
Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease.
Macaluso FS, Grova M, Mocciaro F, Di Mitri R, Privitera AC, Distefano ME, Vitello A, Camilleri S, Ferracane C, Pluchino D, Belluardo N, Giangreco E, Fries W, Viola A, Cappello M, D'Amato L, Bertolami C, Ventimiglia M, Renna S, Casà A, D'Antonio E, De Vivo S, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Macaluso FS, et al. Among authors: casa a. J Gastroenterol Hepatol. 2023 Sep;38(9):1503-1509. doi: 10.1111/jgh.16208. Epub 2023 May 6. J Gastroenterol Hepatol. 2023. PMID: 37148148
MITE display.
Casa AM, Nagel A, Wessler SR. Casa AM, et al. Methods Mol Biol. 2004;260:175-88. doi: 10.1385/1-59259-755-6:175. Methods Mol Biol. 2004. PMID: 15020809
Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.
Macaluso FS, Giuliano A, Fries W, Viola A, Abbruzzese A, Cappello M, Giuffrida E, Carrozza L, Privitera AC, Magnano A, Ferracane C, Scalisi G, Minissale MG, Giangreco E, Garufi S, Bertolami C, Cucinotta U, Graziano F, Casà A, Renna S, Teresi G, Rizzuto G, Mannino M, Maida M, Orlando A. Macaluso FS, et al. Among authors: casa a. Inflamm Bowel Dis. 2023 Feb 1;29(2):217-221. doi: 10.1093/ibd/izac064. Inflamm Bowel Dis. 2023. PMID: 35385102 Free PMC article.
Letter: mesalazine-a safe drug with rare serious adverse events.
Scrivo B, Renna S, Casà A, Monachino N, Macaluso FS, Orlando A. Scrivo B, et al. Among authors: casa a. Aliment Pharmacol Ther. 2020 Jun;51(11):1210-1211. doi: 10.1111/apt.15691. Aliment Pharmacol Ther. 2020. PMID: 32424923 No abstract available.
Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort study.
Macaluso FS, Fries W, Viola A, De Francesco C, Belluardo N, Giangreco E, Cappello M, Ajovalasit R, Mocciaro F, Scrivo B, Privitera AC, Distefano ME, Vitello A, Ferracane C, Muscarella S, Li Voti R, Mistretta G, Renna S, Casà A, Ventimiglia M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Macaluso FS, et al. Among authors: casa a. Dig Liver Dis. 2025 Nov;57(11):2109-2113. doi: 10.1016/j.dld.2025.07.037. Epub 2025 Aug 26. Dig Liver Dis. 2025. PMID: 40866141
SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501.
Macaluso FS, Cappello M, Busacca A, Fries W, Viola A, Costantino G, Magnano A, Vinci E, Ferracane C, Privitera AC, Piccillo G, Belluardo N, Giangreco E, Romano C, Citrano M, Graziano F, Garufi S, Bertolami C, Ventimiglia M, Scrivo B, Teresi G, Renna S, Rizzuto G, Casà A, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Macaluso FS, et al. Among authors: casa a. J Gastroenterol Hepatol. 2021 Nov;36(11):3041-3049. doi: 10.1111/jgh.15590. Epub 2021 Jul 3. J Gastroenterol Hepatol. 2021. PMID: 34152636
77 results